Madrigal Pharmaceuticals, Inc.
MDGL
Clasificación en acciones
#2013
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Precio por acción
$446.50
Última sincronización: 2026-10-19
Capitalización bursátil
$10.32B
Cambio (1 día)
-0.72%
Cambio (1 año)
1.48%
País
US
Comercio Madrigal Pharmaceuticals, Inc. (MDGL)
Categoría
Healthcare
Número de acciones en circulación de Madrigal Pharmaceuticals, Inc. (MDGL)
Número de acciones en circulación al June 2026: 29.15M
Según los últimos informes financieros y el precio de las acciones de Madrigal Pharmaceuticals, Inc., el número actual de acciones en circulación es 29.15M. Al final de December 2023, la empresa tenía 18.69M acciones en circulación. El número de acciones en circulación generalmente se ve afectado por divisiones de acciones y recompras.
Historial de acciones en circulación de Madrigal Pharmaceuticals, Inc. (MDGL) desde 2001 hasta 2026
Acciones en circulación al final de cada año
| Año | Acciones en circulación | Cambiar |
|---|---|---|
| 2026 (TTM) | 29.15M | 37.01% |
| 2024 | 21.27M | 13.83% |
| 2023 | 18.69M | 9.05% |
| 2022 | 17.14M | 3.64% |
| 2021 | 16.54M | 7.04% |
| 2020 | 15.45M | 0.34% |
| 2019 | 15.40M | 4.04% |
| 2018 | 14.80M | 20.84% |
| 2017 | 12.25M | 135.25% |
| 2016 | 5.21M | 2,943.65% |
| 2015 | 171.01K | -93.92% |
| 2014 | 2.81M | 38.76% |
| 2013 | 2.03M | 19.51% |
| 2012 | 1.70M | 25.89% |
| 2011 | 1.35M | 16.91% |
| 2010 | 1.15M | 19.09% |
| 2009 | 968.21K | 0.45% |
| 2008 | 963.86K | 3.91% |
| 2007 | 927.59K | 45.81% |
| 2006 | 636.14K | 0.05% |
| 2005 | 635.80K | 18.98% |
| 2004 | 534.39K | -14.41% |
| 2003 | 624.37K | 81.48% |
| 2002 | 344.04K | 310.87% |
| 2001 | 83.74K | 0.00% |
Acciones en circulación de empresas similares o competidores
| Empresa | Acciones en circulación | Diferencia | País |
|---|---|---|---|
| 253.90M | 771.15% |
US
|
|
| 396.00M | 1,258.71% |
US
|
|
| 478.91M | 1,543.19% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 113.36% |
NL
|
